This topic was covered a while back briefly as a piece of hope surrounding new entrants to the market however thought i would highlight some findings from the patent itself that gave me some fresh hope.
The drug in question is Bayer's PRL receptor anti-body drug that specifically targets the PRL receptor.
"PRLR-mediated signaling plays a role in a variety of processes such as mammary gland development, lactation, reproduction, mammary and prostate tumor growth, autoimmune diseases, general growth and metabolism, and immunomodulation"
It was speculated in the last post on this topic that the drug wouldn't be effective because these traits were assumed to be linked to prolactin itself. Dopamine agonists such as Cabergoline that suppress prolactin have no beneficial effect for Androgenetic Alopecia hinting this would be equally ineffective.
However, it appears the actual supression of serum prolactin itself is not a metric for effectiveness ...
"The pituitary PRL secretion can be inhibited by use of bromocriptine and other dopamine receptor 2 agonists. These agents, however, do not suppress extrapituitary PRL synthesis that can compensate successfully for the inhibition of pituitary PRL synthesis leading to almost unimpaired PRLR-mediated signalling"
As for results when trialed on stumptail macaques it was found that over a 6 month period results of hair growth did not peak during the 6 month time period. A drastic increase of the terminal hair count in bald areas (109 % increase) was demonstrated as well as an increase in transition areas.
Not exactly new news however in light of RCH-01 being a let down this might be of some comfort for the future.
Patent : https://patents.google.com/patent/WO2019011719A1/en
The drug in question is Bayer's PRL receptor anti-body drug that specifically targets the PRL receptor.
"PRLR-mediated signaling plays a role in a variety of processes such as mammary gland development, lactation, reproduction, mammary and prostate tumor growth, autoimmune diseases, general growth and metabolism, and immunomodulation"
It was speculated in the last post on this topic that the drug wouldn't be effective because these traits were assumed to be linked to prolactin itself. Dopamine agonists such as Cabergoline that suppress prolactin have no beneficial effect for Androgenetic Alopecia hinting this would be equally ineffective.
However, it appears the actual supression of serum prolactin itself is not a metric for effectiveness ...
"The pituitary PRL secretion can be inhibited by use of bromocriptine and other dopamine receptor 2 agonists. These agents, however, do not suppress extrapituitary PRL synthesis that can compensate successfully for the inhibition of pituitary PRL synthesis leading to almost unimpaired PRLR-mediated signalling"
As for results when trialed on stumptail macaques it was found that over a 6 month period results of hair growth did not peak during the 6 month time period. A drastic increase of the terminal hair count in bald areas (109 % increase) was demonstrated as well as an increase in transition areas.
Not exactly new news however in light of RCH-01 being a let down this might be of some comfort for the future.
Patent : https://patents.google.com/patent/WO2019011719A1/en
Last edited:
